Influencing Appropriate Statin Use in a Charity Care Primary Clinic

Hasitha Diana Manohar1, Carole Karkour2, Rajesh N Desai2

  • 1Department of Internal Medicine, Loyola University Medical Center, Maywood, IL 60153, USA.

Insights

This study improved statin prescription for diabetes and atherosclerotic cardiovascular disease patients by 25% using a systematic approach. The findings support faster adoption of cholesterol management guidelines.

Area of Science:

  • Cardiovascular Medicine
  • Clinical Pharmacy
  • Health Services Research

Background:

  • New 2019 ACC/AHA guidelines show low statin prescription rates (46.4% for DM, 30% for ASCVD).
  • Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of death and disability.
  • Systematic interventions to improve statin adherence for ASCVD are understudied.

Purpose of the Study:

  • To address the research gap in systematic interventions for statin adherence in ASCVD.
  • To investigate the role of pharmacy, providers, E.M.R., and patients in improving cholesterol management with statins.
  • To pave the way for future research on cardiovascular and statin regimens.

Main Methods:

  • Qualitative observational study conducted in a US northeastern charity care primary clinic.
  • Utilized electronic health records (EHR) and electronic prescribing (E-Scribe).
  • Implemented four Plan-Do-Study-Act (PDSA) cycles over six months, intensifying interventions with each cycle.

Main Results:

  • Achieved a 25% relative improvement in appropriate statin prescription for ASCVD or DM patients within six months.
  • Baseline appropriate statin dosing: 77% for cardiovascular disease patients, 80.4% for diabetes patients.
  • PDSA cycles demonstrated potential for faster uptake and support of ACC/AHA guidelines.

Conclusions:

  • PDSA cycles can significantly improve appropriate statin prescription rates in primary care settings.
  • Overcoming barriers like over-prescription and time constraints is crucial for guideline adherence.
  • Proactive panel management is key to optimizing statin utilization for cardiovascular risk reduction.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
747
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
22
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
20
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
15
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31